White House Pulls FDA Nominee Heidi Overton One Day Before Her Confirmation Vote
Dr. Heidi Overton's bid to lead the FDA collapsed under Republican opposition tied to her role in Trump's vaccine schedule overhaul, with a Senate health panel vote just a day away.
The White House withdrew the nomination of Dr. Heidi Overton to lead the Food and Drug Administration on Tuesday, pulling the plug just one day before a Senate committee vote that officials feared she would lose.
Overton, a White House Domestic Policy Council aide whom Trump had tapped in August to run the FDA, lacked enough Republican votes on the Senate Health, Education, Labor and Pensions Committee to survive Wednesday's scheduled markup, according to STAT News. Republicans hold only a one-vote majority on the panel, meaning a single defection — combined with unified Democratic opposition — would have been enough to sink her nomination outright.
Vaccine policy became the flashpoint
The opposition centered less on Overton's qualifications than on her proximity to the administration's reshaping of childhood vaccine policy. She stood beside Trump last summer when he announced an executive order to reduce and separate the childhood vaccine schedule, a move that alarmed mainstream physician groups and, from the opposite direction, failed to satisfy vaccine skeptics inside the administration's own coalition. Health Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" movement also came out against her, arguing she would not go far enough in challenging pharmaceutical industry interests once in office, according to The Hill.
Senate HELP Committee Chairman Bill Cassidy, a physician himself, had publicly aired concerns about Overton's nomination for weeks, controlling whether it would even reach a committee vote. The White House initially vowed to press ahead despite his objections, but officials ultimately concluded this week that the numbers simply weren't there.
SHE LACKED SUFFICIENT SUPPORT FROM REPUBLICANS ON THE SENATE'S HEALTH PANEL
It is the second FDA-adjacent nomination the administration has had to abandon this year; the White House previously withdrew its pick for surgeon general, Casey Means, after she also fell short on committee votes. The pattern underscores how thin the Senate Republican margin has become on health nominations tangled up in the administration's broader vaccine-policy fights.
According to NBC New York, officials have not said who might be nominated next. Semafor has reported the administration is weighing Sen. Roger Marshall, a Kansas Republican and physician, as a possible replacement, though nothing has been finalized. In the meantime, the FDA continues to operate under an acting leader as the search for a permanent commissioner starts over from scratch — the second time in less than a year the agency has been left without a confirmed chief.
For an administration that has made remaking federal health policy a centerpiece of its second term, the withdrawal is an embarrassing setback, one that exposes how difficult it has become to find a nominee who satisfies both establishment Republicans and the vaccine-skeptic wing that holds outsized influence over health appointments.